Clinical drug trials may be key to reducing macular edema

Baltimore-Macular edema is the final common pathway for visual loss in many diseases, but so far, available treatments have not been effective in improving visual acuity to 20/20 in a significant percentage of patients, according to Julia A. Haller, MD, who spoke during the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine, here.